The authors sincerely acknowledge that an incorrect image panel was inadvertently included in Figs. 2G and 3B of the originally published article in EBioMedicine.1 In addition, the authors have noticed that the supplemental material file was a wrong version in track changes without Supplemental Figure S2. To ensure the accuracy and integrity of the article, the authors have carefully reviewed the original data and replaced the erroneous images.
Fig. 2G.
TCF7 knockdown inhibited the proliferation, migration, and invasion of PHCC cells. (A and B) TCF7 expression in different human cholangiocarcinoma cell lines, gallbladder carcinoma cell lines, HIBEpiC cells, and HepG2 cells were as detected with qRT-PCR (A) and western blotting (B). (C and D) Successful knockdown of TCF7 by two independent siRNAs was verified with qRT-PCR (C) and western blotting (D) in QBC-939 and FRH-0201 PHCC cells. (E and F) CCK8 assays (E) and colony formation assays (F) to determine the effects of TCF7 silencing on the proliferation of QBC-939 and FRH-0201 cells. (G) Transwell invasion assays in QBC-939 and FRH-0201 cells with TCF7 knockdown. Scale bar: 200 μm. (H) Wound healing assays in QBC-939 and FRH-0201 cells with TCF7 knockdown. Data in (E–H) were from at least three independent experiments and are shown as means ± SEMs. Statistical significance was analyzed using Student's t-tests; ∗, ∗∗, and ∗∗∗ indicate P < 0.05, P < 0.01, and P < 0.001, respectively, compared with the control group transfected with scrambled siRNA. (I) Western blotting showing the successful establishment of QBC-939 cell lines with stable TCF7 knockdown using the two indicated shRNAs. (J) Stable QBC-939-TCF7i cells and control cells (transfected with empty vector) were injected subcutaneously into the right flanks of BALB/c nude mice (n = 6/group). Three weeks after implantation, xenograft tumors were observed in the three groups. (K) Tumor volumes of xenografts were measured every 3 days. (L) Weights of xenograft tumors after 21 days. ∗, ∗∗, and ∗∗∗ indicate P < 0.05, P < 0.01, and P < 0.001, respectively, compared with the control group transfected with empty vector. Statistical significance was analyzed with Student's t-tests.
Fig. 3B.
c-Myc was required for TCF7-induced proliferation, migration, and invasion. (A) After silencing or overexpressing TCF7 in QBC-939 cells, expression levels of c-Myc, CCND1, and MMP7 were detected by western blotting. (B) Representative c-Myc IHC staining in xenograft tumors with transfection of empty vector or shTCF7. Scale bar: 50 μm. (C) mRNA level of c-Myc in control xenografts and xenografts with TCF7 knockdown. (D) Correlation of IHC scores for TCF7 and c-Myc in PHCC tissues. (E) Association of c-Myc mRNA levels with TCF7 levels in eight fresh human PHCCs. (F) Effects of Wnt agonist 1 (20 μM, 8 h) on TCF7 and c-Myc expression in QBC-939 cells. (G) Expression of c-Myc was knocked down in normal QBC939 cells or QBC-939 cells overexpressing TCF7. (H) CCK8 assays showing the effects of c-Myc silencing and Wnt agonist 1 on proliferation in QBC-939 cells. ∗ and ∗∗ represent P < 0.05 and P < 0.01, respectively, between the indicated subgroups. (I) Effects of TCF7 knockdown, TCF7 overexpression, and c-Myc knockdown on colony formation ability in QBC-939 cells. (J and K) Effects of c-Myc knockdown with TCF7 overexpression or Wnt agonist 1 stimulation on soft agar transwell assays (J) and wound healing assays (K) in QBC-939 cells. ∗, ∗∗, and ∗∗∗ indicate P < 0.05, P < 0.01, and P < 0.001, respectively, compared with the corresponding control groups. # and ## represent P < 0.05 and P < 0.01, respectively, between the indicated groups. Analyzed data were from at least three independent experiments.
Supplemental Figure 2.
A and B. TCF7 knockdown of xenografts transfected with shTCF7 was confirmed by western blotting (A) and qRT-PCR (B). ∗∗∗ indicates P < 0.001, analyzed by t test.
This correction does not affect the main findings or conclusions of the study. The revised figures and their corresponding legends are provided below.
Contributor Information
Yunfei Xu, Email: xuyunfei1988@126.com.
Zongli Zhang, Email: zzlzzl1900@163.com.
Reference
- 1.Zengli L., Rongqi S., Xiaoming Z., et al. Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1. eBioMedicine. 2019;45:181–191. doi: 10.1016/j.ebiom.2019.06.023. [DOI] [PMC free article] [PubMed] [Google Scholar]



